Head and Neck Squamous Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Head and Neck Squamous Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) [Phase 2]
Phase 2 clinical trial evaluating sacituzumab govitecan in combination with cetuximab for head and neck squamous cell cancers is currently r…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial [Phase 2]
This ClinicalTrials.gov listing describes a Phase II randomized trial (FAST) evaluating 3-5 Fraction Stereotactic Body Radiation Therapy for…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 clinical trial update for PF-07265028 as a single agent and in combination with sasanlimab in advanced/metastatic solid tumors has b…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
Tasca Therapeutics is testing CP-383 in a Phase 1/2 trial for patients with advanced or metastatic solid tumors, including colorectal cancer…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) [Phase 2]
A single-arm Phase II trial (SAVED) in p16-positive oropharyngeal cancer evaluating selective dose de-escalation of nodal and primary-site r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial [Phase 2]
Phase 2 clinical trial evaluating olanzapine to manage cancer-associated anorexia in head and neck cancer patients undergoing chemoradiation…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 2]
A Phase 2 trial comparing postoperative adjuvant radiochemotherapy with cisplatin alone versus cisplatin plus pembrolizumab in locally advan…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality [NA]
A clinical trial is investigating virtual reality 3D-surgery modeling to enhance the quality of head and neck squamous cell carcinoma surger…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors [Phase 1]
Phase 1 study of intravenous QEQ278 in patients with advanced solid tumors has been terminated.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation [Phase 1]
This clinical trial update states that CLSP-1025 is being evaluated in a Phase 1 study for adults with solid tumors harboring the p53 R175H …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
This ClinicalTrials.gov entry describes a study by A2 Biotherapeutics evaluating HLA LOH analysis and apheresis for CAR-T cell manufacturing…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer [Phase 2]
Phase 2 study evaluating tadalafil in combination with pembrolizumab in recurrent or metastatic head and neck cancer has completed enrollmen…
-
EMA approval · 2026-02-12EMA Authorised: Foscan (temoporfin) — Biolitec Pharma Ltd
The European Medicines Agency authorised Foscan (temoporfin) for head and neck squamous cell carcinoma, with Biolitec Pharma Ltd as the mark…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma [NA]
A Yonsei University-led clinical trial update investigating immune determinants of response to nivolumab in recurrent or metastatic head and…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study [Phase 2]
A Phase 2 trial (The Knight SHIFT Study) is comparing morning versus afternoon administration of immunotherapy for advanced or metastatic so…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 2]
Phase 2 clinical trial update describing two single-arm cohorts in recurrent/metastatic head and neck squamous cell carcinoma, focusing on c…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors [Phase 1]
Phase 1 study update for NRM-823 in locally advanced or metastatic refractory solid tumors, currently recruiting. The trial lists head and n…
-
CLINICAL_TRIALS other · 2026-02-12Clinical Trial Update: The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
A recruiting clinical trial called RESCUE is evaluating survival and functional outcomes after salvage surgery for residual or recurrent hea…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial [Phase 2]
This document outlines a Phase 2 clinical trial (LAPP Trial) investigating the combination of lovastatin and pembrolizumab for recurrent or …
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas [Phase 2]
Phase 2 trial investigating reducing the number of chemotherapy cycles in combination with pembrolizumab as first-line treatment for PD-L1–p…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC [Phase 2]
Phase 2 neoadjuvant chemoimmunotherapy trial for resectable head and neck squamous cell carcinoma using camrelizumab with paclitaxel and car…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: H101 Plus TACE for r/m HNSCC [Phase 2]
This entry notes a Phase 2 trial evaluating H101 in combination with transarterial chemoembolization (TACE) for recurrent/metastatic head an…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]
This document provides an update on a Phase 2 clinical trial evaluating cemiplimab in combination with low-dose paclitaxel and carboplatin f…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC [Phase 2]
A Phase 2 clinical trial is evaluating pulsed-dose chemotherapy in combination with pembrolizumab for recurrent/metastatic head and neck squ…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors [Phase 2]
A Phase 2 study evaluating vobramitamab duocarmazine in metastatic castration-resistant prostate cancer and other solid tumors was terminate…